Journal
JOURNAL OF RHEUMATOLOGY
Volume 41, Issue 5, Pages 945-954Publisher
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.130378
Keywords
HYALURONIC ACID; OSTEOBLASTS; METALLOPROTEINASES; ADAMTS; TISSUE INHIBITOR OF METALLOPROTEINASES; RANK LIGAND
Categories
Ask authors/readers for more resources
Objective. To determine the effect of hyaluronic acid (HA) on proteolytic enzymes and bone remodeling mediators induced by interleukin 1 beta (IL-1 beta) and related to cartilage catabolism in murine osteoblasts. Methods. Osteoblasts were obtained from Swiss mice and cultured for 3 weeks. HA-treated osteoblasts were incubated with 100 mu g/ml HA during the last week of culture, then stimulated with IL-1 beta (10 ng/ml) for 24 h. The expression of matrix metalloproteinases 3 and 13 (MMP-3 and MMP-13), ADAMTS-4 and ADAMTS-5, tissue inhibitor of metalloproteinases (TIMP), osteo-protegerin, and receptor activator of nuclear factor-kappa B ligand (RANKL) was determined by real-time polymerase chain reaction. MMP-3 and MMP-13 release was assessed by Western blot analysis. Results. IL-1 beta increased the mRNA levels of MMP-3 and MMP-13 and ADAMTS-4 and ADAMTS-5 and release of MMP-3 and MMP-13. Seven days of HA treatment significantly prevented the IL-1 beta-increased mRNA levels of MMP-3 (-61%, p < 0.01), MMP-13 (-56%, p < 0.01), ADAMTS-4 (-58%, p < 0.05), ADAMTS-5 (-52%, p < 0.01), and RANKL (-49%, p < 0.05), but not TIMP. As well, IL-1 beta-induced production of MMP-3 and MMP-13 was inhibited, by 27% (p < 0.01) and 40% (p < 0.01), respectively. Conclusion. In an inflammatory context in murine osteoblasts, HA can inhibit the expression of MMP and ADAMTS. Because HA can counteract the production of these mediators in chondrocytes, its beneficial effect in osteoarthritis may be due to its action on cartilage and subchondral bone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available